| Avanish Vellanki |
Founder of Rain Oncology, Inc. and Independence Brewing Co. Pvt Ltd., Avanish Vellanki currently holds the position of Chairman & Chief Executive Officer at Rain Oncology, Inc.
In his past career Mr. Vellanki occupied the position of Chairman of Independence Brewing Co. Pvt Ltd., Chief Business Officer & Senior Vice President at Aptose Biosciences, Inc., Senior Vice President at Wedbush Securities, Inc., Vice President at Citigroup Global Markets, Inc., Senior Director-Corporate Development at Proteolix, Inc. and Associate for Bear, Stearns & Co., Inc.
Mr. Vellanki received an undergraduate degree from Carleton College, a graduate degree from the University of Minnesota and an MBA from The Curtis L. Carlson School of Management. |
| Robert Doebele |
Robert Doebele is the founder of Rain Oncology, Inc., which was founded in 2017. He holds the title of President & Chief Scientific & Medical Officer at Rain Oncology, Inc. Currently, Dr. Doebele is also working as the Director-Thoracic Oncology Research Initiative at the University of Colorado Cancer Center since 2017. In terms of education, Dr. Doebele has a graduate degree and a doctorate from the University of Pennsylvania, conferred in 1998 and 2001 respectively. He also has an undergraduate degree from Princeton University, conferred in 1993. |
| Nelson D. Cabatuan |
Currently, Nelson D. Cabatuan occupies the position of Chief Financial Officer of Lexaria Bioscience Corp. and Senior Vice President-Operations & Finance at Rain Oncology, Inc.
In the past he held the position of Chief Accounting Officer, VP & Controller for Rigel Pharmaceuticals, Inc. and Senior Manager at Grant Thornton LLP.
He received an undergraduate degree from Pamantasan Ng Lungsod Ng Maynila. |
| Erik Atkisson |
Erik Atkisson is currently the General Counsel & Chief Compliance Officer at Rain Oncology, Inc. Prior to this, he was the Chief Compliance Officer at Cytokinetics, Inc. He also served as the Secretary & General Counsel at Eiger BioPharmaceuticals, Inc. from 2021 to 2023. Mr. Atkisson received his undergraduate degree from Harvard University, his graduate degree from The University of Edinburgh, and his law degree from Georgetown University Law Center. |
| Zack Malkin |
Zack is a Venture Partner at Lightbank, where he is responsible for leading investments, as well as helping Lightbank deepen its footprint in health tech and biotechnology markets. Zack is also SVP Finance at Pathos, a clinical-stage AI-driven oncology therapeutics development platform and Lightbank portfolio company.
Prior to joining Lightbank and Pathos, Zack was a Principal at Victory Park Capital, where he invested across the capital structure in early to growth-stage venture companies across a wide range of sectors and asset classes. Zack began his career in the Transaction Advisory Services group at EY as a strategic advisor focused on complex healthcare transactions. He is active in philanthropy supporting causes related to colorectal cancer, and has a finance degree from the University of Texas at Austin. |
| Lucio Tozzi |
Lucio Tozzi's current job(s) include Senior Vice President-Clinical Operations at Rain Oncology, Inc. since 2021 and Senior Vice President-Global Clinical Operations at ProKidney Corp. since 2024. Formerly, Mr. Tozzi worked as Director-Clinical Operations at Baxter Healthcare Corp. from 2005 to 2014, Senior Medical Director-Clinical Science at Onyx Pharmaceuticals, Inc. from 2008 to 2012, Senior Director & Head-Clinical Operations at Astex Pharmaceuticals, Inc. from 2014 to 2015, Vice President-Clinical Operations at Protagonist Therapeutics, Inc. from 2015 to 2019, and as Principal-Clinical Research Services at Parkwood Advisors LLC in 2014. Mr. Tozzi obtained his undergraduate degree from Royal Holloway University of London in 1986. |
| Ryan Fukushima |
Ryan Fukushima is the founder of Pathos AI, Inc. (founded in 2021) and serves as the Chief Executive Officer & Director. He is currently the Chief Executive Officer at Rain Oncology, Inc. and the Chief Operating Officer at Tempus AI, Inc. since 2015. Mr. Fukushima has previously worked as a Principal at Michigan Ross Zell Lurie Institute, an Associate at TechStars Central, LLC, a Principal at Tapjoy, Inc., and a Vice President at Lightbank LLC from 2014 to 2016. He has also held positions as an Associate at Huron River Venture Partners LLC and as a Senior Associate at Hyde Park Venture Partners Management LLC from 2013 to 2014. Mr. Fukushima holds an MBA from the University of Michigan and a graduate degree from the University of Michigan. He also has an undergraduate degree from California Polytechnic State University (San Luis Obispo) and an MBA from the Stephen M. Ross School of Business. |
| Gorjan Hrustanovic |
Currently, Gorjan Hrustanovic occupies the position of Managing Director at BVF Partners LP. Dr. Hrustanovic is also on the board of Nimbus Therapeutics LLC, Kymera Therapeutics, Inc., Rain Oncology, Inc. and Olema Pharmaceuticals, Inc.
In the past Dr. Hrustanovic was Member-Observer Board at 4D Molecular Therapeutics, Inc.
He received an undergraduate degree from the University of California San Diego and a doctorate from The University of California, San Francisco. |
| Tran B. Nguyen |
Currently, Tran B. Nguyen is Chief Financial & Strategy Officer at Prothena Corp. Plc. Mr. Nguyen is also on the board of Rain Oncology, Inc.
In his past career Mr. Nguyen occupied the position of Vice President at Citigroup, Inc. and VP-Healthcare Investment Banking Group at Citigroup Global Markets, Inc. (a subsidiary of Citigroup, Inc.), CFO, Secretary, Treasurer, CAO & VP-Finance at Metabasis Therapeutics, Inc., Chief Financial Officer, Senior VP & Head-IR at Somaxon Pharmaceuticals, Inc. and VP-Healthcare Investment Banking Group at Lehman Brothers, Inc.
He received an undergraduate degree from Claremont McKenna College and an MBA from UCLA Anderson School of Management. |
| Stefani A. Wolff |
Stefani A. Wolff is on the board of Rain Oncology, Inc. She previously held the position of Chief Operating Officer & EVP-Product Development at Nurix Therapeutics, Inc., Product Manager at Eli Lilly & Co., Principal at BioPharma Consulting Services LLC, Vice President-Development at Onyx Pharmaceuticals, Inc. and Chief Development Officer of Principia Biopharma, Inc.
Stefani A. Wolff received an undergraduate degree from The University of North Carolina at Charlotte. |
| Peter Radovich |
Currently, Peter Radovich is President & Chief Operating Officer at Mirum Pharmaceuticals, Inc. He is also on the board of Rain Oncology, Inc.
In the past Mr. Radovich was Senior Vice President-Operations at Global Blood Therapeutics, Inc., Principal at Chiron Corp. and Senior Director & VP-Program Leadership at Onyx Pharmaceuticals, Inc.
He received an MBA from the University of Washington and an undergraduate degree from Texas Christian University. |
| Aaron I. Davis |
Aaron I. Davis is a businessperson who founded Boxer Capital LLC and who has been at the helm of 5 different companies. Currently, he is Executive Chairman at CiVi Biopharma, Inc. and Executive Chairman at CiVi Biopharma Holdings, Inc. (a subsidiary of CiVi Biopharma, Inc.), Chief Executive Officer at Boxer Capital LLC and Chief Executive Officer of MVA Investors LLC. Aaron I. Davis is also on the board of 5 other companies.
Mr. Davis previously occupied the position of Chairman & Chief Executive Officer for BCTG Acquisition Corp., Principal at UBS Securities LLC, Portfolio Manager at Tavistock Group, Inc. (United States) and Vice President at Tavistock Life Sciences Co.
Mr. Davis received a graduate degree from The Trustees of Columbia University in The City of New York and an undergraduate degree from Emory University. |
